New antibody shows promise for rare blood cancers
NCT ID NCT03902184
First seen May 13, 2026 · Last updated Jun 22, 2026 · Updated 6 times
Summary
This phase 2 trial tested a drug called lacutamab (IPH4102) in 170 people with advanced T-cell lymphoma, including Sezary syndrome and mycosis fungoides. The drug targets a protein on cancer cells to help control the disease. Participants received the drug alone or with chemotherapy to see if it shrinks tumors and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOSIS FUNGOIDES/SEZARY SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ASST degli Spedali Civili di Brescia
Brescia, 25123, Italy
-
CET Centrum Medyczne Pratia Poznan ul. Poznanska 14
Skorzewo, 60-185, Poland
-
CHRU de Lille - Hopital Claude Huriez
Lille, 59037, France
-
CHRU de Montpellier - Hopital Saint Eloi
Montpellier, 34095, France
-
CHRU de Tours, Hôpital Trousseau
Chambray-lès-Tours, 37170, France
-
CHU Henri Mondor
Créteil, 94010, France
-
CHU de Bordeaux Saint André
Bordeaux, 33075, France
-
Centre Hospitalier Lyon-Sud
Lyon, 69310, France
-
Centre Hospitalier Universitaire (CHU) de Liege
Liège, 4000, Belgium
-
Charite - Universitaetsmedizin Berlin
Berlin, 10115, Germany
-
Columbia University Department of Dermatology
New York, New York, 10032, United States
-
Consorci Hospital General Universitari de Valencia Servicio de Dermatología
Valencia, 46014, Spain
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03756, United States
-
Hospital Clinic Barcelona
Barcelona, 08036, Spain
-
Hospital Clinico Universitario de Salamanca
Salamanca, 37007, Spain
-
Hospital Universitari i Politecnic La Fe
Valencia, 46026, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital del Mar
Barcelona, 08003, Spain
-
Hôpital Charles Nicolle-CHU de Rouen Clinique Dermatologie
Rouen, 76031, France
-
Hôpital Saint-Louis
Paris, 75010, France
-
IUCT Oncopôle
Toulouse, 31100, France
-
Inova Health Care Services
Fairfax, Virginia, 22031, United States
-
Institut Jules Bordet
Brussels, 1070, Belgium
-
Institut Paoli-Calmettes
Marseille, 13009, France
-
Institute of Hematology "Seràgnoli", Univeristy of Bologna
Bologna, 40138, Italy
-
Irvine Medical Center
Orange, California, 92868, United States
-
Istituto Dermopatico dell'Immacolata (IDI-IRCCS)
Roma, 00167, Italy
-
Johannes Wesling Klinikum Minden
Minden, 32429, Germany
-
MD Anderson Cancer Center
Houston, Texas, 77030-4009, United States
-
Medizinische Universitaet Wien
Vienna, 1090, Austria
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Klinika Nowotworow Ukladu Chlonnego
Warsaw, 02-781, Poland
-
Northwestern University The Feinberg School of Medicine
Chicago, Illinois, 60611, United States
-
Ruhr-University Bochum
Bochum, 44791, Germany
-
Stanford University
Stanford, California, 94305, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
UZ Leuven - campus Gasthuisberg
Leuven, 3000, Belgium
-
Universal Dermatology, PLLC68
Fairport, New York, 14450, United States
-
Universita di Torino, Ospedale le Molinette
Turin, 10126, Italy
-
Universitaetsklinikum Halle (Saale)
Halle, 06120, Germany
-
Universitaetsklinikum Muenster
Münster, 48149, Germany
-
Universitaetsklinikum Schleswig-Holstein Campus Kiel
Kiel, 24105, Germany
-
Universitaetsmedizin Mannheim GmbH
Mannheim, 68167, Germany
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
University of California, Los Angeles (UCLA) - Medical Center
Los Angeles, California, 90095, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania, 15208, United States
-
University of South Florida
Tampa, Florida, 33612, United States
-
Universitätsklinik für Dermatologie Medizinische Universität Graz
Graz, A-8036, Austria
-
Universitätsklinikum Frankfurt
Frankfurt, 60590, Germany
-
Uniwersyteckie Centrum Kliniczne, Klinika Dermatologii, Wenerologii i Alergologii ul. Smoluchowskiego 17
Gdansk, 80-214, Poland
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lacutamab (IPH4102), a monoclonal antibody
What this could lead to
If successful, this could provide a new treatment option for patients with advanced T-cell lymphoma who have run out of standard therapies.
What could go wrong
This is a mid-stage trial with 170 participants, so results are not yet definitive. The drug may not work for all patients, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.